Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.

Xiaoyan HanXincheng JiangJingsong HeGaofeng ZhengYaqin XiongYanling WenYang YangDonghua HeQingxiao ChenYi ZhaoYi LiWenjun WuZhen Cai

Published in: Cancer medicine (2024)

In real-world settings, Pom-based, Dara-based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara-based therapy yielded superior clinical response and PFS compared to Pom-based therapy.

Keyphrases

multiple myeloma
stem cells
acute myeloid leukemia
bone marrow
mesenchymal stem cells
hodgkin lymphoma
smoking cessation